Clinical trial
131MIBG to Treat Malignant Pheochromocytoma
NCT00028106 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH · Completed
Key facts
| NCT number | NCT00028106 |
|---|---|
| Title | 131MIBG to Treat Malignant Pheochromocytoma |
| Official title | (131)I-Metaiodobenzylguanidine Treatment of Malignant Pheochromocytoma |
| Lead sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pheochromocytoma |
| Intervention type | Drug |
| Interventions | [131]I-MIBG, 6-[18F]Fluorodopamine, [123]I-MIBG |
| Enrollment | 32 |
| Start date | Dec 5, 2001 |
| Completion | Jan 8, 2007 |
| First posted | Dec 12, 2001 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: